PMID- 21978916 OWN - NLM STAT- MEDLINE DCOM- 20121015 LR - 20240406 IS - 1872-9738 (Electronic) IS - 0892-0362 (Print) IS - 0892-0362 (Linking) VI - 34 IP - 1 DP - 2012 Jan-Feb TI - Prenatal exposure to MDMA alters noradrenergic neurodevelopment in the rat. PG - 206-13 LID - 10.1016/j.ntt.2011.09.005 [doi] AB - 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) binds with high affinity to the norepinephrine transporter (NET), making the noradrenergic system a potential target during fetal exposure. Recent data indicate that adult rats that had been prenatally exposed to MDMA display persistent deficits in working memory and attention; behaviors consistent with abnormal noradrenergic signaling in the forebrain. The present study was designed to investigate whether prenatal exposure to MDMA from embryonic days 14-20 affects the structure and/or function of the noradrenergic system of the rat on postnatal day 21. Offspring that were prenatally exposed to MDMA exhibited an increase in noradrenergic fiber density in the prelimbic region of the prefrontal cortex and the CA1 region of the hippocampus that was not accompanied by an increase in the number of noradrenergic neurons in the locus coeruleus. Direct tissue autoradiography using tritiated nisoxetine demonstrated that while NET binding was not altered in the prelimbic cortex, the dentate gyrus, or the locus coeruleus, it was increased in the CA1, CA2, and CA3 regions of the hippocampus. Basal levels of norepinephrine were increased in the prefrontal cortex and the nucleus accumbens of MDMA-exposed rats, as compared to saline-treated controls. These findings indicate that prenatal exposure to MDMA results in structural changes in the noradrenergic system as well as functional alterations in NE neurotransmission in structures that are critical in attentional processing. CI - Copyright (c) 2011 Elsevier Inc. All rights reserved. FAU - Thompson, V B AU - Thompson VB AD - Neuroscience Graduate Program, University of Cincinnati, Cincinnati, OH, USA. valerie.thompson@emory.edu FAU - Koprich, J B AU - Koprich JB FAU - Chen, E Y AU - Chen EY FAU - Kordower, J H AU - Kordower JH FAU - Terpstra, B T AU - Terpstra BT FAU - Lipton, J W AU - Lipton JW LA - eng GR - 1R21DA019261/DA/NIDA NIH HHS/United States GR - R21 DA019261/DA/NIDA NIH HHS/United States GR - R21 DA019261-01/DA/NIDA NIH HHS/United States GR - 1R01DA017399/DA/NIDA NIH HHS/United States GR - R01 DA017399-05/DA/NIDA NIH HHS/United States GR - R01 DA017399/DA/NIDA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20110928 PL - United States TA - Neurotoxicol Teratol JT - Neurotoxicology and teratology JID - 8709538 RN - 0 (Adrenergic Uptake Inhibitors) RN - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine) SB - IM MH - Adrenergic Neurons/*drug effects/*pathology MH - Adrenergic Uptake Inhibitors/*toxicity MH - Animals MH - Animals, Newborn MH - Cell Count MH - Cell Differentiation/drug effects/physiology MH - Disease Models, Animal MH - Female MH - Male MH - Microscopy/methods MH - N-Methyl-3,4-methylenedioxyamphetamine/*toxicity MH - Nerve Fibers, Myelinated/pathology MH - Neurogenesis/*drug effects/physiology MH - Neurotoxicity Syndromes/pathology/*physiopathology MH - Pregnancy MH - Prenatal Exposure Delayed Effects/metabolism/pathology/*physiopathology MH - Rats MH - Rats, Sprague-Dawley PMC - PMC3268906 MID - NIHMS328605 COIS- Conflict of Interest Statement: The authors declare that there are no conflicts of interest. EDAT- 2011/10/08 06:00 MHDA- 2012/10/16 06:00 PMCR- 2013/01/01 CRDT- 2011/10/08 06:00 PHST- 2011/04/18 00:00 [received] PHST- 2011/09/16 00:00 [revised] PHST- 2011/09/20 00:00 [accepted] PHST- 2011/10/08 06:00 [entrez] PHST- 2011/10/08 06:00 [pubmed] PHST- 2012/10/16 06:00 [medline] PHST- 2013/01/01 00:00 [pmc-release] AID - S0892-0362(11)00192-9 [pii] AID - 10.1016/j.ntt.2011.09.005 [doi] PST - ppublish SO - Neurotoxicol Teratol. 2012 Jan-Feb;34(1):206-13. doi: 10.1016/j.ntt.2011.09.005. Epub 2011 Sep 28.